15.12.2015 • NewsElaine BurridgeVaccinesSanofi Pasteur

Sanofi Gets Approval for World’s First Dengue Vaccine

Mexico has granted marketing authorization to Sanofi Pasteur for its dengue vaccine, Dengvaxia. The vaccine is the world’s first to be approved for preventing the disease which is transmitted by mosquitoes.

Dengvaxia has been developed to protect against all four dengue virus serotypes in people from nine to 45 years of age living in endemic areas. According to the World Health Organization (WHO), dengue is the world’s fastest growing mosquito-borne disease, infecting nearly 400 million people every year and causing severe bone and joint pain. The WHO has asked endemic countries to reduce dengue mortality by 50% and morbidity by 25% by 2020.

“Dengue is a growing health threat in Mexico and many other tropic and subtropical countries in Latin America and Asia. The first vaccine approved to prevent dengue fever is a major innovation and a public health breakthrough,” said Jose Luis Arredondo Garcia, associate director of clinical research in Mexico’s National Institute of Pediatrics.

The vaccine’s approval is based on results from an extensive clinical development program involving more than 40,000 people in 15 countries, including Mexico.

First doses of Dengvaxia have been produced at Sanofi’s facility in France and full-scale capacity will reach 100 million vaccine doses annually.

Regulatory reviews are ongoing in other endemic countries.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.